Junichiro Yuda

Kashiwa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.

Journal: International journal of clinical oncology

Published: June 14, 2026

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implications.

Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implications.

Journal: mAbs

Published: April 28, 2026

Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study.

Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study.

Journal: Cureus

Published: March 20, 2026

Molecular Relapse After a Second Treatment-Free Remission Attempt Following Asciminib in Chronic Myeloid Leukemia: A Case Report.

Molecular Relapse After a Second Treatment-Free Remission Attempt Following Asciminib in Chronic Myeloid Leukemia: A Case Report.

Journal: Case reports in hematology

Published: March 08, 2026

SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies.

SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies.

Journal: International journal of clinical oncology

Published: February 12, 2026

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Journal: Frontiers in oncology

Published: February 01, 2026

Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).

Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).

Journal: International journal of clinical oncology

Published: November 21, 2025

Novel agents for acute myeloid leukemia not yet approved in Japan

Novel agents for acute myeloid leukemia not yet approved in Japan

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: November 05, 2025

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.

Journal: Cancer science

Published: August 26, 2025

A Long-Term Survival Case of Acute Myeloid Leukemia With MYC-Positive Double Minute Chromosomes.

A Long-Term Survival Case of Acute Myeloid Leukemia With MYC-Positive Double Minute Chromosomes.

Journal: Cureus

Published: August 09, 2025

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Journal: Blood cancer journal

Published: July 08, 2025

Showing 1-12 of 52

Last Updated: 09/26/2026